Pharming Group (PHGUF) has released an update.
Pharming Group has reported a robust second quarter in 2024 with a revenue increase of 35% to US$74.1 million, driven by significant growth in its drugs RUCONEST® and Joenja®. The company is on track to reach its 2024 revenue guidance of US$280-295 million. Despite a decline in cash reserves due to bond refinancing, the momentum is expected to continue positively throughout the year.
For further insights into PHGUF stock, check out TipRanks’ Stock Analysis page.
